ArticleAnnals of intensive care2011
Corticosteroids for severe sepsis: an evidence-based guide for physicians.
Article in Annals of intensive care, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.
- Continuous versus Intermittent Hydrocortisone for the Treatment of Septic Shock: A Systematic Review and Meta-Analysis.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2026Pooled it
- Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers.The AAPS journal · 2017Trial
- Trial
- ARF6 inhibition stabilizes the vasculature and enhances survival during endotoxic shock.Journal of immunology (Baltimore, Md. : 1950) · 2014Trial
- Reverse-Engineered Lipid Nanoparticles Harness Protein Corona Formation for Cytokine Sequestration and Combination Immunomodulatory Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Corticosteroids in severe community-acquired pneumonia: friend, foe or both?Pneumonia (Nathan Qld.) · 2026Review
- Fluvoxamine attenuates inflammation in experimental sepsis via novel non-canonical pathways.Inflammopharmacology · 2026Article
- Immune Dysregulation in Sepsis. A Narrative Review for the Clinicians.Biomedicines · 2025Review
- Norepinephrine Versus Dopamine as a First-Line Vasopressor in Dogs with Hypotension: A Pilot Study.Veterinary sciences · 2025Article
- Article
- The Role of PI3k-Gamma Modulation in Bacterial Infection: A Review of the Literature and Selected Experimental Observations.Antibiotics (Basel, Switzerland) · 2025Review
- Haemodynamic management of septic shock.Burns & trauma · 2025Review
- Influence of hydrocortisone infusion method on the clinical outcome of patients with septic shock: A systematic review and meta-analysis.Journal of intensive medicine · 2025Article
- Review
- Bactericidal antibiotic treatment induces damaging inflammation via TLR9 sensing of bacterial DNA.Nature communications · 2024Article
- Recent trends in septic shock management: a narrative review of current evidence and recommendations.Annals of medicine and surgery (2012) · 2024Review
- Review
- Recent Data about the Use of Corticosteroids in Sepsis-Review of Recent Literature.Biomedicines · 2024Review
- Critical illness-related corticosteroid insufficiency (CIRCI) in paediatric patients: a diagnostic and therapeutic challenge.Italian journal of pediatrics · 2024Review
- Current perspectives in the management of sepsis and septic shock.Frontiers in medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Septic shock is characterized by uncontrolled systemic inflammation that contributes to the progression of organ failures and eventually death. There is now ample evidence that the inability of the host to mount an appropriate hypothalamic-pituitary and adrenal axis response plays a major in overwhelming systemic inflammation during infections. Proinflammatory mediators released in the inflamed sites oppose to the anti-inflammatory response, an effect that may be reversed by exogenous corticosteroids. With sepsis, via nongenomic and genomic effects, corticosteroids restore cardiovascular homeostasis, terminate systemic and tissue inflammation, restore organ function, and prevent death. These effects of corticosteroids have been consistently found in animal studies and in most recent frequentist and Bayesian meta-analyses. Corticosteroids should be initiated only in patients with sepsis who require 0.5 μg/kg per minute or more of norepinephrine and should be continued for 5 to 7 days except in patients with poor hemodynamic response after 2 days of corticosteroids and with a cortisol increment of more than 250 nmol/L after a standard adrenocorticotropin hormone (ACTH) test. Hydrocortisone should be given at a daily dose of 200 mg and preferably combined to enteral fludrocortisone at a dose of 50 μg. Blood glucose levels should be kept below 150 mg/dL.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.